Neurotensin agonists: potential in the treatment of schizophrenia.

CNS Drugs

Neuropsychopharmacology Laboratory, Mayo Foundation for Medical Education and Research, Mayo Clinic Jacksonville, Florida 32224, USA.

Published: May 2007

Neurotensin (NT) is a neuropeptide that, for decades, has been implicated in the biology of schizophrenia. It is closely associated with, and is thought to modulate, dopaminergic and other neurotransmitter systems involved in the pathophysiology of various neuropsychiatric diseases, including schizophrenia. This review outlines the neurochemistry and function of the NT system and the data implicating its role in schizophrenia. The data suggest that NT receptor agonists have the potential to be used as novel therapeutic agents for the treatment of schizophrenia, with the added benefits of (i) not causing weight gain, an adverse effect that is problematic with some of the currently used atypical antipsychotic drugs; and (ii) helping patients to stop smoking, a behaviour that is highly prevalent in those with schizophrenia.

Download full-text PDF

Source
http://dx.doi.org/10.2165/00023210-200721010-00002DOI Listing

Publication Analysis

Top Keywords

agonists potential
8
treatment schizophrenia
8
schizophrenia
6
neurotensin agonists
4
potential treatment
4
schizophrenia neurotensin
4
neurotensin neuropeptide
4
neuropeptide decades
4
decades implicated
4
implicated biology
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!